Replies to post #68900 on Bioelectronics Corp (BIEL)

[JustGoDeep]

Thursdays Company Update says the FDA is still in review. Check the Facts.

[JustGoDeep]

The-Facts the Whole Facts and Nothing But FACTS

The Facts for the Factually challenged.

Ready the line under the bullet points number 1 2 3

BioElectronics Update

BioElectronics Company Update – Thursday, January 7, 2016
ActiPatch® Pain Therapy Available at 102 Showcase Stores in Canada

Showcase (www.shopatshowcasecanada.com), founded in 1994 in Edmonton AB, is the Home of the Hottest Trends and is the world's largest retailer of its kind offering the most fun, interactive, new and unique products. Showcase stores are located in the best shopping centres coast to coast across Canada.

Chris Russell, President of Chris-Kelly, LLC, stated, “We are excited to have a retail partner like Showcase in Canada. Amin Jivraj, Founder of Showcase, stated, “At Showcase, we bring to consumers emerging trends in health, beauty, and home, all in an environment where you can “try it before you buy it”. ActiPatch offers an ingenious solution to pain relief and we are proud to introduce it to our customers.”

BioElectronics Announces Publication of Breakthrough Clinical Study for Drug-free Treatment of Chronic Osteoarthritis

The recent publication of this clinical study demonstrates the efficacy of ActiPatch® Therapy for knee osteoarthritis. It further validates the positive effects of negating chronic pain central sensitization by noninvasive neuromodulation therapy. The technology is affordable, effective, and a safe alternative to prescription opioid therapy that is drastically needed in the US, and by the 1.5 billion worldwide chronic pain sufferers.

Oxford University Press, on behalf of the British Society of Rheumatology, published the study in their journal Rheumatology (www.rheumatology.oxfordjournals.org). The study was an independently conducted, double blind, placebo-controlled, randomized clinical trial. A statistically significant reduction in pain and improvement in the WOMAC² physical assessments was reported. In addition, patients in the treatment group displayed a reduced use of NSAIDs³ and an improvement in their quality of life compared to the placebo group.

“The data from this comprehensive clinical study shows ActiPatch's ability to improve the management of osteoarthritis of the knee." said Ian Rawe, Ph.D., Director of Clinical Research. “We sincerely thank the clinical scientists who conducted this study led by Dr. Gianluca Bagnato, Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Messina, Italy.”

This study further demonstrates the noninvasive neuromodulation of ActiPatch® Therapy as the pain pressure threshold increased. This data, along with positive treatment of chronic pain reported in our other studies and the recent published registry study, A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag 2015 Vov; 5(6), 413-23 (www.bielcorp.com/clinical-evidence) supports our growing evidence that ActiPatch® Therapy negates central sensitization, a core component of chronic pain. It also shows successful self-management of chronic pain in arthritis, musculoskeletal, and other chronic pain conditions.

The published peer reviewed article can be viewed at: http://rheumatology.oxfordjournals.org/content/early/2015/12/23/rheumatology.kev426.long

Central sensitization - a condition wherein the central nervous system mediated pain pathways become hypersensitive
WOMAC - Western Ontario and McMaster Universities Osteoarthritis Index
NSAIDs – Nonsteroidal anti-inflammatory drugs

Studies published in prestigious peer reviewed medical journals such as “Rheumatology” have significant credence. A copy has been forwarded to the U.S. FDA to validate the study in our pending over-the-counter market clearance application.

BioElectronics Announces Oxford University Sponsored Study for Chronic Low Back Pain

Oxford University is sponsoring a clinical trial on chronic lower back pain using ActiPatch® Therapy. Chronic low back pain is a major health problem and has significant associated healthcare costs, accounting for more than £12 billion in direct and indirect costs every year in the United Kingdom [1].

The study is a randomized, double blind, placebo controlled crossover trial to assess the efficacy of ActiPatch on 30 individuals with chronic back pain at Oxford’s John Radcliffe Hospital. Each subject will undergo 2 weeks of active therapy or two weeks of placebo therapy. After a 1 week break, the treatment will be reversed to provide all subjects with active therapy and act as their own controls. The study is registered with the U.S. National Institutes of Health. https://www.clinicaltrials.gov/ct2/show/NCT02601807?term=ActiPatch&rank=1

Professor Tipu Aziz is the principal investigator who will be leading the study. Professor Aziz is the head and founder of Oxford functional neurosurgery and the author of over 200 scientific publications. He was elected Fellow of the Academy of Medical Sciences in 2013.

The use of ActiPatch® Therapy by chronic pain sufferers is expanding rapidly in the UK giving a safe drug free and economical alternative therapy for people to manage their chronic pain,” said Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics. “It is very encouraging that an institute of the caliber of the Oxford University is sponsoring a clinical trial to demonstrate the efficacy of ActiPatch® Therapy for chronic back pain. Clearly a positive demonstration of efficacy for chronic back pain back will have major implications.”

1. Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain 84(1), 95–103 (2000).

[JustGoDeep]

At least the opening Statement is True!!

FDA is Coming!!

[DewmBoom]

The Cash flow in 2016 will buy the A/S multiple times at current price.

Also, the 510K is still under review by the FDA. The fact that it is still under review is a great news. The OTC is requested for multiple use and may require more documentation and/or information. So, I don't expect the clearance to take place before Q2 2016.

As we discussed earlier and you agreed that Biel will be a multi billion dollar company based on international sale alone. The huge cash flow from international sale is coming our way in 2016.


Stay Knee and Back actipatched very very tightly before the big news hit the news stand. Thank for your high interest in Biel.


Very Very Strong Buy

[nayanala]

Show proof ir better refrain from wild false accusations. That's what wise investors do

[nayanala]

The lies..more lies and nothing but lies